July 26, 2017

Oncolytics Biotech to Present REOLYSIN Safety Data

Oncolytics Biotech announced two abstracts describing both pooled safety and tolerability data and the mechanism of REOLYSIN will be presented...
December 19, 2016

Loxo Oncology Outlines Plans for Accelerated Path to US FDA Approval for Larotrectinib

Loxo Oncology today announced a comprehensive program update for larotrectinib (LOXO-101), a selective inhibitor of tropomyosin receptor kinase (TRK), and...
December 9, 2016

Novartis LEE011 (ribociclib) Plus Letrozole Analyses Show Superior PFS in First-Line HR+/HER2- Advanced Breast Cancer

Novartis announced today additional analyses from the Phase III MONALEESA-2 study that show LEE011 (ribociclib) plus letrozole significantly prolonged progression-free...
November 13, 2016

5 Top NASDAQ Biotech Stocks: PTC Therapeutics Gains 88 Percent

Last week's top gainer was PTC Therapeutics followed by Cogentix Medical, Concordia International, Galectin Therapeutics and XOMA.
November 7, 2016

Dynavax Reports Third Quarter 2016 Financial Results and Company Update

Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter and nine months ended September 30, 2016.
November 6, 2016

5 Top NASDAQ Biotech Stocks: AveXis, Inc. Leads

Last week's top gainer was AveXis, Inc. followed by Heska Corp., Corcept Therapeutics, Atara Biotherapeutics and Seattle Genetics Inc.
October 30, 2016

5 Top NASDAQ Biotech Stocks: Alexion Pharmaceuticals Leads

Last week's top gainer was Alexion Pharmaceuticals, followed by LeMaitre Vascular, NeoGenomics Inc, United Therapeutics Corp. and Mesa Laboratories.